[go: up one dir, main page]

NZ624708A - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents

Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Info

Publication number
NZ624708A
NZ624708A NZ624708A NZ62470811A NZ624708A NZ 624708 A NZ624708 A NZ 624708A NZ 624708 A NZ624708 A NZ 624708A NZ 62470811 A NZ62470811 A NZ 62470811A NZ 624708 A NZ624708 A NZ 624708A
Authority
NZ
New Zealand
Prior art keywords
urate
lowering agent
halofenate
methods
gout
Prior art date
Application number
NZ624708A
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of NZ624708A publication Critical patent/NZ624708A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent such as febuxostat. In some aspects the first urate-lowering agent is (-)- halofenate, (-)- halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
NZ624708A 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent NZ624708A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (1)

Publication Number Publication Date
NZ624708A true NZ624708A (en) 2015-11-27

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ624708A NZ624708A (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Country Status (13)

Country Link
EP (1) EP2773336A4 (en)
JP (1) JP6202633B2 (en)
KR (1) KR20140121383A (en)
CN (2) CN104066427A (en)
AU (1) AU2011380507B2 (en)
CA (1) CA2859686C (en)
CL (1) CL2014001155A1 (en)
IL (1) IL232386A0 (en)
MX (1) MX357507B (en)
NZ (1) NZ624708A (en)
SG (1) SG11201402032RA (en)
WO (1) WO2013066349A1 (en)
ZA (1) ZA201403575B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013245675B2 (en) * 2012-04-13 2017-02-09 Cymabay Therapeutics, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
JP6368756B2 (en) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Method of treating hyperuricemia in patients suffering from gout using halofenate or halofenic acid and a second uric acid lowering drug
CN108014108A (en) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 The application of lesinurad or its pharmaceutically acceptable salt in the medicine for treating or preventing Cushing syndrome is prepared
WO2019082335A1 (en) * 2017-10-26 2019-05-02 大塚製薬株式会社 Inositol phosphate-containing composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US9023856B2 (en) * 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent

Also Published As

Publication number Publication date
CN109908124A (en) 2019-06-21
AU2011380507B2 (en) 2017-06-15
EP2773336A4 (en) 2015-06-03
MX2014005400A (en) 2015-02-12
JP6202633B2 (en) 2017-09-27
CA2859686A1 (en) 2013-05-10
IL232386A0 (en) 2014-06-30
ZA201403575B (en) 2015-11-25
KR20140121383A (en) 2014-10-15
SG11201402032RA (en) 2014-09-26
CL2014001155A1 (en) 2015-01-16
EP2773336A1 (en) 2014-09-10
AU2011380507A1 (en) 2014-05-29
WO2013066349A1 (en) 2013-05-10
CA2859686C (en) 2018-09-11
JP2014532758A (en) 2014-12-08
CN104066427A (en) 2014-09-24
MX357507B (en) 2018-07-12

Similar Documents

Publication Publication Date Title
JP2012184234A5 (en)
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
MA37400A1 (en) Cyclil compounds are not heterogeneous as mek inhibitors
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
NZ601121A (en) 5-alkynyl-pyrimidines
EA201200793A1 (en) TREATMENT OF GENOTYPED PATIENTS WITH DIABETES DPP-4 INHIBITORS, SUCH AS LINAGLIPTIN
BR112013014914A2 (en) compound, pharmaceutical composition, method of treating cancer in a patient and use
AU2011201462B2 (en) Method of Administering Pirfenidone Therapy
EA201201648A1 (en) SGC STIMULATORS
MX336381B (en) Boronates as arginase inhibitors.
PE20170306A1 (en) NEW MODIFIED RELEASE DOSAGE FORMS OF A XANTHINE OXIDOR REDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS
EA201490377A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
MY182983A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
EP2583969A4 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
MX2012009600A (en) Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors.
EA201490928A1 (en) METHODS OF TREATMENT FOR ACUTE GUTTERS
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2022009874A (en) HETEROCYCLIC INHIBITORS OF PEPTIDYL ARGININE DEIMINASE 4 (PAD4).
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.
JP2014532758A5 (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 NOV 2018 BY AJ PARK

Effective date: 20160502

ASS Change of ownership

Owner name: CYMABAY THERAPEUTICS, INC., US

Effective date: 20170309

Owner name: DIATEX, INC., NZ

Effective date: 20170309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2019 BY CPA GLOBAL

Effective date: 20180920

LAPS Patent lapsed